Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis

Few therapy options exist for patients with advanced papillary and anaplastic thyroid cancer. We and others have previously identified c-Src as a key mediator of thyroid cancer pro-tumorigenic processes and a promising therapeutic target for thyroid cancer. To increase the efficacy of targeting Src...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2019-04, Vol.38 (14), p.2565-2579
Hauptverfasser:	Kessler, Brittelle E., Mishall, Katie M., Kellett, Meghan D., Clark, Erin G., Pugazhenthi, Umarani, Pozdeyev, Nikita, Kim, Jihye, Tan, Aik Choon, Schweppe, Rebecca E.
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/21 13/89 631/67/1059/602 631/67/1459/1843 96 96/1 96/106 96/109 96/2 96/95 Apoptosis Apoptosis - genetics Autocrine signalling c-Jun protein Cell Biology Cell Line, Tumor Crk-Associated Substrate Protein - genetics Dasatinib - pharmacology Drug Resistance, Neoplasm - genetics Focal Adhesion Kinase 1 - genetics Gelatinase B Genotype & phenotype Human Genetics Humans IL-1β Inflammation Internal Medicine Invasiveness Kinases Medicine Medicine & Public Health Metalloproteinase Mutation - genetics Oncology Phenotype Phenotypes Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins c-jun - genetics Secretome Signal Transduction - genetics Src protein src-Family Kinases - genetics Therapeutic applications Thyroid cancer Thyroid Neoplasms - drug therapy Thyroid Neoplasms - genetics Transcription factors Tumor cell lines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!